BIV009
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bullous Pemphigoid (BP)
Conditions
Bullous Pemphigoid (BP), Cold Agglutinin Disease (CAD), Warm Autoimmune Hemolytic Anemia (WAIHA), End-stage Renal Disease (ESRD)
Trial Timeline
Jul 13, 2015 → Mar 31, 2021
NCT ID
NCT02502903About BIV009
BIV009 is a phase 1 stage product being developed by Sanofi for Bullous Pemphigoid (BP). The current trial status is completed. This product is registered under clinical trial identifier NCT02502903. Target conditions include Bullous Pemphigoid (BP), Cold Agglutinin Disease (CAD), Warm Autoimmune Hemolytic Anemia (WAIHA).
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02502903 | Phase 1 | Completed |
Competing Products
8 competing products in Bullous Pemphigoid (BP)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ixekizumab | Eli Lilly | Phase 2 | 52 |
| Benralizumab + Placebo | AstraZeneca | Phase 3 | 77 |
| QGE031 + Placebo | Novartis | Phase 2 | 52 |
| Azathioprine or Mycophenolate mofetil | Roche | Phase 2 | 52 |
| dupilumab + Matching Placebo + Oral corticosteroids (OCS) | Sanofi | Phase 2/3 | 64 |
| dupilumab | Sanofi | Pre-clinical | 22 |
| efgartigimod PH20 SC + Prednisone | Argenx | Phase 3 | 74 |
| efgartigimod PH20 SC + Prednisone | Argenx | Phase 2/3 | 62 |